https://crcblueprint.com/colorectal-screening-uptake-hiv-43-percent-meta-analysis/2026-07-30T07:59:17+00:00https://crcblueprint.com/colonoscopy-linked-to-lower-crc-hazard-ages-75-79/2026-07-30T07:59:23+00:00https://crcblueprint.com/segmental-surgery-linked-to-metachronous-cancer-rate-in-lynch-syndrome/2026-07-30T07:58:25+00:00https://crcblueprint.com/ctdna-detection-linked-to-higher-colorectal-cancer-recurrence-risk/2026-07-30T07:58:35+00:00https://crcblueprint.com/84-8-two-year-survival-deceased-donor-transplant-colorectal-liver-metastases/2026-07-30T07:58:41+00:00https://crcblueprint.com/intensified-preoperative-treatment-improved-disease-free-survival-rectal-cancer/2026-07-30T07:58:48+00:00https://crcblueprint.com/aspirin-reduced-dfs-events-pik3ca-exon-9-20-colorectal-tumours/2026-07-30T07:58:56+00:00https://crcblueprint.com/severe-immune-toxicity-linked-higher-response-msi-h-cancers/2026-07-30T07:59:02+00:00https://crcblueprint.com/ai-assistance-adenoma-detection-lynch-syndrome-surveillance/2026-07-30T07:59:09+00:00https://crcblueprint.com/radiation-boost-nine-year-disease-free-survival-rectal-cancer/2026-07-30T08:00:01+00:00https://crcblueprint.com/older-surgical-patients-66-2-percent-five-year-recurrence-free-survival/2026-07-29T09:30:57+00:00https://crcblueprint.com/cetuximab-irinotecan-rechallenge-versus-regorafenib-metastatic-colorectal-cancer/2026-07-29T09:47:41+00:00https://crcblueprint.com/updated-phts-surveillance-guidance-colorectal-cancer-limited-evidence/2026-07-29T09:57:18+00:00https://crcblueprint.com/first-line-immunotherapy-reduced-progression-hazard-msi-h-metastatic-colorectal-cancer/2026-07-30T18:53:01+00:00https://crcblueprint.com/bevacizumab-triplet-top-surgical-conversion-ranking-liver-metastases/2026-07-30T18:57:57+00:00https://crcblueprint.com/tislelizumab-45-3-percent-pathological-complete-response-rectal-cancer-neo-star/2026-07-30T18:52:32+00:00https://crcblueprint.com/saliva-microbiome-model-auc-0780-early-onset-colorectal-cancer/2026-07-30T18:54:12+00:00